TrialArteriosclerosis, thrombosis, and vascular biology2018

Comparative Effects of PCSK9 (Proprotein Convertase Subtilisin/Kexin Type 9) Inhibition and Statins on Postprandial Triglyceride-Rich Lipoprotein Metabolism.

Dick C Chan et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.